KYORIN Pharmaceutical 관리

관리 기준 확인 1/4

KYORIN Pharmaceutical CEO는 Yutaka Ogihara, Jun2019 에 임명되었습니다 의 임기는 5.42 년입니다. 는 ¥ 11.89B 가치에 해당하는 회사 주식의 13.64% 직접 소유합니다. 11.89B. 경영진과 이사회의 평균 재임 기간은 각각 0.8 년과 6.4 년입니다.

주요 정보

Yutaka Ogihara

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	5.4yrs
CEO 소유권	13.6%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	6.4yrs

최근 관리 업데이트

Recent updates

CEO

Yutaka Ogihara (57 yo)

5.4yrs

테뉴어

Mr. Yutaka Ogihara has been Representative Director and President of KYORIN Pharmaceutical Co., Ltd. since June 2019 and serves as its Chief Executive Officer since April 2023. He serves as Chairman of KYO...

리더십 팀

이름	위치	테뉴어	보상	소유권
Yutaka Ogihara	President	5.4yrs	데이터 없음	13.64% ¥ 11.9b
Yasuji Kurose	CFO, CStO	no data	데이터 없음	0.00050% ¥ 436.0k
Junichi Ishiyama	Executive Officer	no data	데이터 없음	데이터 없음
Kiyoo Uehara	Executive Officer	less than a year	데이터 없음	데이터 없음
Michiro Onota	Executive Director & CMO	no data	데이터 없음	0.025% ¥ 22.0m
Takaaki Kaji	Executive Officer & Chief Business Development Officer	no data	데이터 없음	데이터 없음
Noriaki Tamura	Executive Officer	no data	데이터 없음	데이터 없음
Kimiya Masada	Corporate Officer & Director of Product Strategy	less than a year	데이터 없음	데이터 없음
Hiroshi Hashizume	Executive Officer	no data	데이터 없음	데이터 없음
Makoto Yanai	Executive Officer & Deputy GM of Business Development Division	no data	데이터 없음	데이터 없음
Katsuhiro Hamada	Executive Officer & GM of Reliability Assurance Headquarters	no data	데이터 없음	데이터 없음

0.8yrs

평균 재임 기간

경험이 풍부한 관리: 4569 의 관리팀은 경험 (평균 재직 기간 0.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yutaka Ogihara	President	13.4yrs	데이터 없음	13.64% ¥ 11.9b
Yasuji Kurose	CFO, CStO	less than a year	데이터 없음	0.00050% ¥ 436.0k
Michiro Onota	Executive Director & CMO	7.4yrs	데이터 없음	0.025% ¥ 22.0m
Hiroshi Hashizume	Executive Officer	no data	데이터 없음	데이터 없음
Tomiharu Matsumoto	Chairman of Corporate Auditors	6.4yrs	데이터 없음	0.036% ¥ 31.6m
Kenji Akutsu	Full-time Audit & Supervisory Board Member	2.4yrs	데이터 없음	0.023% ¥ 19.8m
Takao Yamaguchi	Outside Audit & Supervisory Board Member	9.4yrs	데이터 없음	0.0043% ¥ 3.8m
Noriyuki Shikanai	Independent Outside Director	11.4yrs	데이터 없음	0.0085% ¥ 7.4m
Ken Shigematsu	Independent Outside Director	7.4yrs	데이터 없음	0.0082% ¥ 7.1m
Hiromi Watanabe	Independent Outside Director	5.4yrs	데이터 없음	0.0040% ¥ 3.5m
Yukio Ikemura	Outside Audit & Supervisory Board Member	2.4yrs	데이터 없음	0.00087% ¥ 758.7k
Kensuke Morita	Outside Audit & Supervisory Board Member	2.4yrs	데이터 없음	0.00087% ¥ 758.7k

6.4yrs

평균 재임 기간

69yo

평균 연령

경험이 풍부한 이사회: 4569 의 이사회는 경험(평균 재직 기간 6.4 년)으로 간주됩니다.

KYORIN Pharmaceutical 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

KYORIN Pharmaceutical Co., Ltd., Annual General Meeting, Jun 21, 2024

KYORIN Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2023

Less than half of directors are independent

KYORIN Holdings, Inc., Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Recent updates

Upcoming dividend of JP¥20.00 per share

Now 21% overvalued

First quarter 2025 earnings released: EPS: JP¥15.41 (vs JP¥11.80 in 1Q 2024)

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

KYORIN Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Consensus EPS estimates fall by 14%, revenue upgraded

Price target decreased by 13% to JP¥1,300

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

KYORIN Pharmaceutical Co., Ltd., Annual General Meeting, Jun 21, 2024

KYORIN Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 10, 2024

KYORIN Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on May 10, 2024

Upcoming dividend of JP¥32.00 per share

Now 20% overvalued

Third quarter 2024 earnings released: EPS: JP¥37.55 (vs JP¥54.71 in 3Q 2023)

New minor risk - Profit margin trend

Second quarter 2024 earnings released: EPS: JP¥18.85 (vs JP¥1.03 in 2Q 2023)

Upcoming dividend of JP¥20.00 per share at 2.9% yield

New minor risk - Profit margin trend

First quarter 2024 earnings released: EPS: JP¥11.80 (vs JP¥20.65 in 1Q 2023)

KYORIN Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 08, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

KYORIN Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2023

Upcoming dividend of JP¥32.00 per share at 3.1% yield

Third quarter 2023 earnings released: EPS: JP¥54.71 (vs JP¥41.22 in 3Q 2022)

Second quarter 2023 earnings released: EPS: JP¥1.03 (vs JP¥10.17 in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: JP¥1.03 (vs JP¥10.17 in 2Q 2022)

Upcoming dividend of JP¥20.00 per share

First quarter 2023 earnings released: EPS: JP¥20.65 (vs JP¥8.06 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

KYORIN Holdings, Inc., Annual General Meeting, Jun 24, 2022

KYORIN Holdings, Inc. to Report Q2, 2023 Results on Nov 09, 2022

Consensus EPS estimates increase by 47%

Less than half of directors are independent

Upcoming dividend of JP¥32.00 per share

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

KYORIN Holdings, Inc. to Report Fiscal Year 2022 Results on May 11, 2022

Second quarter 2022 earnings released: EPS JP¥10.17 (vs JP¥8.88 in 2Q 2021)

Upcoming dividend of JP¥20.00 per share

Consensus EPS estimates fall to JP¥52.53

Price target decreased to JP¥1,700

Full year 2021 earnings released: EPS JP¥107 (vs JP¥107 in FY 2020)

Full year 2021 earnings released: EPS JP¥107 (vs JP¥107 in FY 2020)

Upcoming dividend of JP¥45.00 per share

New 90-day high: JP¥2,019

Third quarter 2021 earnings released: EPS JP¥41.64 (vs JP¥61.80 in 3Q 2020)

KYORIN Holdings, Inc. to Report Fiscal Year 2020 Results on May 12, 2021

New 90-day high: JP¥2,008

Price target raised to JP¥2,100

CEO

테뉴어

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령